# Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

> **NCT02604342** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 119 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Alectinib
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02604342
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-03
- **Primary completion:** 2017-01-26
- **Final completion:** 2018-08-13
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2019-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02604342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02604342, "Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02604342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*